- Trials with a EudraCT protocol (1,498)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (67)
1,498 result(s) found for: Hepatitis A.
Displaying page 40 of 75.
| EudraCT Number: 2021-002147-29 | Sponsor Protocol Number: BO43328 | Start Date*: 2021-11-30 | |||||||||||
| Sponsor Name:Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA | |||||||||||||
| Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) FR (Completed) IT (Completed) NL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-008753-33 | Sponsor Protocol Number: CARISNPP2003 | Start Date*: 2009-04-23 | |||||||||||
| Sponsor Name:Janssen Cilag International NV | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase | |||||||||||||
| Medical condition: Neuropathic Pain in Diabetic Peripheral Neuropathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) PT (Prematurely Ended) BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002714-11 | Sponsor Protocol Number: EORTC 22033-26033 | Start Date*: 2005-06-06 | |||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
| Full Title: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study | |||||||||||||
| Medical condition: Histologically proven low-grade glioma ♦ Astrocytoma WHO grade II (gemistocytic, fibrillary and protoplasmatic) ♦ Oligoastrocytoma WHO grade II ♦ Oligodendroglioma WHO grade II | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Completed) HU (Completed) SE (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2023-000944-46 | Sponsor Protocol Number: 217218 | Start Date*: 2024-05-31 |
| Sponsor Name:GLAXOSMITHKLINE BIOLOGICALS SA | ||
| Full Title: A Phase IIa observer-blind, randomized, controlled, age-de-escalation, single center interventional study to evaluate the safety, reactogenicity, and immune response of the GVGH iNTS vaccine agains... | ||
| Medical condition: Prevention of invasive nontyphoidal Salmonella disease | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-002857-12 | Sponsor Protocol Number: GO40241 | Start Date*: 2018-04-26 | |||||||||||
| Sponsor Name:F. Hoffman-La Roche Ltd. | |||||||||||||
| Full Title: A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY I... | |||||||||||||
| Medical condition: Early Stage Resectable Non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) SI (Trial now transitioned) SE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) HU (Completed) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-005386-13 | Sponsor Protocol Number: ARC-9 | Start Date*: 2021-05-05 | |||||||||||
| Sponsor Name:Arcus Biosciences, Inc. | |||||||||||||
| Full Title: A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer | |||||||||||||
| Medical condition: Metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-003508-12 | Sponsor Protocol Number: 010-01 | Start Date*: 2006-02-28 | |||||||||||
| Sponsor Name:Merck and Co., Inc. | |||||||||||||
| Full Title: Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children | |||||||||||||
| Medical condition: RotaTeq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1 (e.g... | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004304-19 | Sponsor Protocol Number: 117119 | Start Date*: 2015-07-23 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary v... | ||
| Medical condition: Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by Haemophilus influenzae type B (... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2012-004442-15 | Sponsor Protocol Number: HISTORY | Start Date*: 2013-09-11 | ||||||||||||||||
| Sponsor Name:University Leipzig | ||||||||||||||||||
| Full Title: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ... | ||||||||||||||||||
| Medical condition: High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients ... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2012-001055-39 | Sponsor Protocol Number: A3L39 | Start Date*: 2013-11-22 | ||||||||||||||||||||||||||
| Sponsor Name:Sanofi Pasteur SA | ||||||||||||||||||||||||||||
| Full Title: Phase III, multi-center trial in 795 infants in the Czech Republic, Germany, and Spain. Subjects from the Czech Republic and Germany will be randomized in Groups 1 and 2 to receive in a blind-obser... | ||||||||||||||||||||||||||||
| Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DE (Completed) CZ (Completed) ES (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-021994-35 | Sponsor Protocol Number: A4001098 | Start Date*: 2011-06-30 | |||||||||||
| Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
| Full Title: A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis... | |||||||||||||
| Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-001533-17 | Sponsor Protocol Number: EORTC26053-22054 | Start Date*: 2007-06-25 | |||||||||||
| Sponsor Name:EORTC European Organisation for research and treatment of cancer | |||||||||||||
| Full Title: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial. | |||||||||||||
| Medical condition: anaplastic glioma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-002578-31 | Sponsor Protocol Number: X05-AR21-302 | Start Date*: 2005-09-14 |
| Sponsor Name:Sanofi Pasteur MSD S.N.C. | ||
| Full Title: A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to... | ||
| Medical condition: The vaccine is indicated for primary and booster vaccination of children against six infectious diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis caused by 3 types of poliovirus ... | ||
| Disease: | ||
| Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
| Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-001655-39 | Sponsor Protocol Number: GCT1015-07 | Start Date*: 2021-08-17 | |||||||||||
| Sponsor Name:Genmab A/S | |||||||||||||
| Full Title: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer | |||||||||||||
| Medical condition: Second- or Third-Line Recurrent or Metastatic Cervical Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) NO (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) DK (Completed) NL (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-000536-95 | Sponsor Protocol Number: SLx-4090-07-03 | Start Date*: 2007-05-08 | |||||||||||
| Sponsor Name:Surface Logix | |||||||||||||
| Full Title: A randomised, double-blind, placebo controlled study to evaluate the pharmacodynamics, safety, tolerability and pharmacokinetics profile of SLx-4090 over 14 days dosing in subjects with high trigly... | |||||||||||||
| Medical condition: Dyslipidemia/hypertriglyceridemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-019411-37 | Sponsor Protocol Number: FE999906CS11 | Start Date*: 2010-08-30 | |||||||||||
| Sponsor Name:FERRING Arzneimittel GmbH | |||||||||||||
| Full Title: A Prospective, Open Label, Randomised, Parallel Group Trial Comparing the Effects of Highly Purified Menotrophin and Recombinant Follicle Stimulating Hormone (rFSH, Follitropin alpha) Administered ... | |||||||||||||
| Medical condition: Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-002584-90 | Sponsor Protocol Number: D1511C00002 | Start Date*: 2005-08-22 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Spu... | ||
| Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-004497-24 | Sponsor Protocol Number: 106227, 106228, 108736, 108738 | Start Date*: 2006-10-24 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: Observer-blinded, randomised, controlled, phase I/II study, to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccines M72/AS01B and M72/AS02A wh... | ||
| Medical condition: Vaccination against tuberculosis | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-010660-42 | Sponsor Protocol Number: ORA2 | Start Date*: 2009-08-13 |
| Sponsor Name:BOWS Pharmaceuticals AG | ||
| Full Title: A double-blind two part placebo-controlled study consisting of a single ascending and multiple-dose tolerance study of peroral insulin in patients with Type 2 diabetes | ||
| Medical condition: Type 2 diabetes | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-014853-33 | Sponsor Protocol Number: 112266 | Start Date*: 2010-02-12 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-032 (208127/022) in which healthy adults were vaccin... | ||
| Medical condition: Immunisation of healthy adults with Twinrix Adult | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.